Article
Publicly Available
The EFLM European Urinalysis Guideline 2023
-
Timo T. Kouri
,
Walter Hofmann
Published/Copyright:
June 5, 2024
Articles in the same Issue
- Frontmatter
- Editorials
- EFLM European Urinalysis Guideline
- Clinical Chemistry Laboratory Medicine in the post-acute COVID-19 era
- EFLM Guideline
- The EFLM European Urinalysis Guideline 2023
- Review
- Approaching sustainability in Laboratory Medicine
- Opinion Papers
- New reimbursement models to promote better patient outcomes and overall value in laboratory medicine and healthcare
- Screening for sickle cell disease: focus on newborn investigations
- Genetics and Molecular Diagnostics
- The role of Killer immunoglobulin-like receptors (KIRs) in the genetic susceptibility to non-celiac wheat sensitivity (NCWS)
- General Clinical Chemistry and Laboratory Medicine
- Understanding the limitations of your assay using EQA data with serum creatinine as an example
- Add-on testing: stability assessment of 63 biochemical analytes in centrifuged and capped samples stored at 16 °C
- Smartphone swabs as an emerging tool for toxicology testing: a proof-of-concept study in a nightclub
- Allergy: Evaluation of 16 years (2007–2022) results of the shared external quality assessment program in Belgium, Finland, Portugal and The Netherlands
- Cancer Diagnostics
- Monoclonal whole IgG impairs both fibrin and thrombin formation: hemostasis and surface plasmon resonance studies
- Cardiovascular Diseases
- Patients with antiphospholipid syndrome and a first venous or arterial thrombotic event: clinical characteristics, antibody profiles and estimate of the risk of recurrence
- Letters to the Editor
- Familial dysalbuminemic hyperthyroxinemia coexisting with a Grave’s disease: a Belgian case report
- Diagnostic challenge between a frequent polygenic hypocholesterolemia and an unusual Smith Lemli Opitz syndrome related to bi-allelic DHCR7 mutations
- First reported co-occurrence of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia with pseudo Chediak-Higashi anomaly and complex karyotype
- Facing the new IVD Regulation 2017/746: Contract Research Organizations (CROs), key partners of IVDs manufacturers for compliance
- Comprehensive analysis and clinical case studies on pseudoeosinophilia: insights and implications – unraveling the complexity: analytical approaches and clinical significance
- Misdiagnosis of type 2B von Willebrand disease as immune thrombocytopenia in a thrombocytopenic patient
- Biological matrices, reagents and turnaround-time: the full-circle of artificial intelligence in the pre-analytical Phase. Comment on Turcic A, et al., Machine learning to optimize cerebrospinal fluid dilution for analysis of MRZH reaction. CCLM 2024;62:436–41
Articles in the same Issue
- Frontmatter
- Editorials
- EFLM European Urinalysis Guideline
- Clinical Chemistry Laboratory Medicine in the post-acute COVID-19 era
- EFLM Guideline
- The EFLM European Urinalysis Guideline 2023
- Review
- Approaching sustainability in Laboratory Medicine
- Opinion Papers
- New reimbursement models to promote better patient outcomes and overall value in laboratory medicine and healthcare
- Screening for sickle cell disease: focus on newborn investigations
- Genetics and Molecular Diagnostics
- The role of Killer immunoglobulin-like receptors (KIRs) in the genetic susceptibility to non-celiac wheat sensitivity (NCWS)
- General Clinical Chemistry and Laboratory Medicine
- Understanding the limitations of your assay using EQA data with serum creatinine as an example
- Add-on testing: stability assessment of 63 biochemical analytes in centrifuged and capped samples stored at 16 °C
- Smartphone swabs as an emerging tool for toxicology testing: a proof-of-concept study in a nightclub
- Allergy: Evaluation of 16 years (2007–2022) results of the shared external quality assessment program in Belgium, Finland, Portugal and The Netherlands
- Cancer Diagnostics
- Monoclonal whole IgG impairs both fibrin and thrombin formation: hemostasis and surface plasmon resonance studies
- Cardiovascular Diseases
- Patients with antiphospholipid syndrome and a first venous or arterial thrombotic event: clinical characteristics, antibody profiles and estimate of the risk of recurrence
- Letters to the Editor
- Familial dysalbuminemic hyperthyroxinemia coexisting with a Grave’s disease: a Belgian case report
- Diagnostic challenge between a frequent polygenic hypocholesterolemia and an unusual Smith Lemli Opitz syndrome related to bi-allelic DHCR7 mutations
- First reported co-occurrence of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia with pseudo Chediak-Higashi anomaly and complex karyotype
- Facing the new IVD Regulation 2017/746: Contract Research Organizations (CROs), key partners of IVDs manufacturers for compliance
- Comprehensive analysis and clinical case studies on pseudoeosinophilia: insights and implications – unraveling the complexity: analytical approaches and clinical significance
- Misdiagnosis of type 2B von Willebrand disease as immune thrombocytopenia in a thrombocytopenic patient
- Biological matrices, reagents and turnaround-time: the full-circle of artificial intelligence in the pre-analytical Phase. Comment on Turcic A, et al., Machine learning to optimize cerebrospinal fluid dilution for analysis of MRZH reaction. CCLM 2024;62:436–41
